In the BioHarmony Drug Report Database
Prialt (ziconotide) is a protein pharmaceutical. Ziconotide was first approved as Prialt on 2004-12-28. It is used to treat chronic pain in the USA. It has been approved in Europe to treat pain and spinal injections. It is known to target voltage-dependent N-type calcium channel subunit alpha-1B and voltage-dependent P/Q-type calcium channel subunit alpha-1A. Prialt’s patent is valid until 2024-10-01 (FDA).
Image (chem structure or protein)